Skip to main content
. 2019 Sep 6;79(14):1583–1590. doi: 10.1007/s40265-019-01195-w

Fig. 1.

Fig. 1

Most common (incidence ≥ 15% in the active treatment group) adverse events of any grade or cause in patients with metastatic gastric cancer who received trifluridine/tipiracil (n = 335) or placebo (n = 168) in the phase III TAGS trial [16]. No grade ≥ 3 thrombocytopenia, leucopenia or neutropenia was reported in the placebo group. AE adverse event, FTD/TPI trifluridine/tipiracil